Lux to develop corneal rejection prevention implant

Article

Lux Biosciences has entered into an exclusive worldwide license agreement with the US National Institutes of Health (NIH) to acquire intellectual property rights for a cyclosporine A (CsA) eluting silicone matrix ocular implant, LX201. The candidate is to be tested for the prevention of rejection following corneal transplantation.

Lux Biosciences has entered into an exclusive worldwide license agreement with the US National Institutes of Health (NIH) to acquire intellectual property rights for a cyclosporine A (CsA) eluting silicone matrix ocular implant, LX201. The candidate is to be tested for the prevention of rejection following corneal transplantation.

In addition to the agreement, the Commission of Orphan Medicinal Products (COMP) has recommended that LX201 receive European orphan drug designation. As a result of this, Lux expects to initiate pivotal trials in early 2007, with an estimated New Drug Application (NDA) submission scheduled for early 2009.

LX201 is a silicone matrix ocular implant that steadily releases therapeutic doses of CsA locally to the eye over the course of twelve months. CsA is already widely used as a systemic therapy for the prevention of organ rejection.

Local delivery of CsA through LX201 offers potentially significant benefits in the treatment of corneal transplantation because of the increased safety and efficacy associated with local administration, as well as enhanced patient compliance.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.